To understand why kratom alkaloids have attracted pharmacological attention, it is necessary to first understand the receptor systems they interact with. Opioid receptors are among the most extensively studied receptor families in biomedical science, not because of kratom, but because they govern fundamental aspects of pain, reward, stress response, and autonomic function. Kratom alkaloid research is a chapter within the larger story of opioid receptor biology.
This article provides an educational overview of opioid receptor biology: what these receptors are, where they are located, how they signal, and why the distinction between different signalling pathways has become a central question in contemporary pharmacology.
What Are Opioid Receptors?
Opioid receptors are a family of G protein-coupled receptors (GPCRs), a class of cell-surface proteins that detect molecular signals outside the cell and activate intracellular responses. GPCRs are the largest family of drug targets in pharmacology; approximately 34% of all approved medications act on GPCR targets.
The opioid receptor family consists of four members, identified in the early 1990s through molecular cloning:
- Mu-opioid receptor (MOR, also written as mu or OPRM1): the primary target of classical analgesic opioids
- Delta-opioid receptor (DOR, OPRD1): involved in mood regulation, pain modulation, and neuroprotection
- Kappa-opioid receptor (KOR, OPRK1): associated with pain, stress response, and dysphoric states
- Nociceptin/orphanin FQ receptor (NOP, OPRL1): the most recently characterised; involved in pain, anxiety, and stress
All four receptors are activated by endogenous opioid peptides, naturally occurring compounds the body produces, including endorphins, enkephalins, dynorphins, and nociceptin. The opioid system is not a drug response system; it is a fundamental part of human physiology that existed before any external opioid compounds were ever used.
Where Opioid Receptors Are Located
Understanding the distribution of opioid receptors explains why opioid compounds produce such a wide range of physiological effects and why the adverse effect profile of classical opioids is so broad.
Central Nervous System
MOR is densely expressed in regions of the brain involved in pain processing (periaqueductal grey, rostral ventromedial medulla), reward and motivation (nucleus accumbens, ventral tegmental area), and respiration (pre-Botzinger complex in the brainstem). DOR is expressed in the limbic system and cortex. KOR is prominent in the limbic system and hypothalamus. The broad CNS distribution of MOR in particular is why mu-opioid agonists produce simultaneous effects on pain, mood, reward, and breathing.
Peripheral Nervous System
Opioid receptors are also expressed on peripheral sensory neurons, the nerve fibres that transmit pain signals from tissue to the spinal cord. This peripheral distribution has been a significant area of research interest because opioid receptor activation at peripheral sites can produce analgesic effects without engaging CNS receptors, potentially reducing CNS-mediated adverse effects.
Gastrointestinal Tract
The enteric nervous system, the network of neurons governing gut function, expresses high levels of MOR. MOR activation in the gut slows intestinal motility. This is the direct mechanism behind opioid-induced constipation, one of the most common and persistent adverse effects of opioid therapy, and explains why loperamide (an MOR agonist that does not cross the blood-brain barrier) is effective as an antidiarrhoeal agent.
How Opioid Receptors Signal: The G Protein Pathway
When an opioid compound, whether endogenous or exogenous, binds to an opioid receptor, it induces a conformational change in the receptor protein that activates the associated G protein on the intracellular side of the cell membrane. Opioid receptors are primarily coupled to inhibitory G proteins (Gi/Go).
Gi/Go activation produces several intracellular effects:
- Inhibition of adenylyl cyclase, reducing intracellular cyclic AMP (cAMP) levels
- Activation of inward-rectifying potassium channels, hyperpolarising the cell and reducing neuronal firing
- Inhibition of voltage-gated calcium channels, reducing neurotransmitter release
The net result of these signalling events is reduced neuronal excitability and decreased neurotransmitter release, which in pain-processing circuits translates to reduced pain signal transmission. This is the core mechanism of opioid analgesia.
The Beta-Arrestin Pathway: A Second Signalling Route
G protein signalling is not the only pathway activated when opioid receptors are engaged. Following receptor activation and G protein signalling, the receptor is typically phosphorylated by G protein-coupled receptor kinases (GRKs). This phosphorylation creates a binding site for beta-arrestin proteins.
Beta-arrestin recruitment serves two primary functions: it terminates G protein signalling (receptor desensitisation) and it initiates its own independent signalling cascade. Beta-arrestin signalling has been associated in preclinical research with several of the most clinically problematic aspects of opioid therapy:
- Respiratory depression: the primary mechanism of fatal opioid overdose, involves beta-arrestin-2 in animal models
- Opioid-induced constipation involves beta-arrestin-2 signalling in the gut
- Tolerance development: the process by which repeated opioid exposure reduces analgesic effect, involves receptor internalisation and downregulation mediated in part by beta-arrestin
- Potential contribution to the reinforcing properties that underlie addiction risk
Biased Agonism: Why the Signalling Pathway Distinction Matters
The observation that G protein signalling and beta-arrestin signalling produce different downstream effects has led to a significant research hypothesis: if it were possible to develop opioid receptor agonists that preferentially activate G protein signalling while minimising beta-arrestin recruitment, those compounds might retain analgesic activity while reducing the adverse effects associated with the beta-arrestin pathway.
This concept, called ‘biased agonism’ or ‘functional selectivity’, became a major focus of opioid pharmacology research in the 2000s and 2010s. The hypothesis generated substantial academic and pharmaceutical industry investment in the search for G-protein-biased MOR agonists.
Kratom alkaloids, particularly 7-hydroxymitragynine, entered this research landscape because preclinical studies found evidence of reduced beta-arrestin-2 recruitment relative to classical opioids. This placed kratom alkaloid research within a broader academic conversation about whether biased agonism at MOR could translate to a different clinical profile.
It is important to note that the biased agonism hypothesis has been challenged by subsequent research. Studies with drugs explicitly designed as G-protein biased agonists have produced mixed results in clinical settings, suggesting the relationship between beta-arrestin bias in vitro and clinical outcomes in humans is more complex than early models predicted. This is an active and unresolved area of pharmacological science.
Receptor Desensitisation, Tolerance, and Physical Dependence
Repeated activation of opioid receptors by exogenous agonists triggers adaptive responses in the receptor system. These adaptations are the molecular basis of tolerance and physical dependence, two distinct phenomena that are often confused.
Tolerance refers to the reduction in pharmacological effect following repeated exposure, requiring higher doses to achieve the same response. At the receptor level, tolerance involves receptor desensitisation (reduced signalling efficiency per receptor), internalisation (removal of receptors from the cell surface), and downregulation (reduced receptor expression).
Physical dependence refers to the physiological state in which the body has adapted to the presence of an opioid compound such that abrupt discontinuation produces withdrawal symptoms. Physical dependence is not the same as addiction, it is a predictable physiological adaptation that occurs with many classes of medications, including beta-blockers and corticosteroids, and does not imply compulsive drug-seeking behaviour.
Addiction is a more complex phenomenon involving compulsive drug use despite adverse consequences, driven by neuroadaptations in reward circuitry that go beyond receptor-level changes alone. Understanding these distinctions is important for accurately interpreting research on opioid compounds, including kratom alkaloids.